Summary
- Merck’s experimental RSV treatment showed positive results in a mid- to late-stage trial
- The treatment reduced RSV-related hospitalizations by over 84% and lowered respiratory infections by 90%
- Merck plans to make the treatment available for infants as early as the 2025 to 2026 RSV season
- The treatment could potentially compete with a similar one from Sanofi and AstraZeneca